CA2197466A1 - Compositions - Google Patents

Compositions

Info

Publication number
CA2197466A1
CA2197466A1 CA002197466A CA2197466A CA2197466A1 CA 2197466 A1 CA2197466 A1 CA 2197466A1 CA 002197466 A CA002197466 A CA 002197466A CA 2197466 A CA2197466 A CA 2197466A CA 2197466 A1 CA2197466 A1 CA 2197466A1
Authority
CA
Canada
Prior art keywords
physiologically tolerable
composition
manganese
acid
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002197466A
Other languages
English (en)
Inventor
Klaes Golman
Goran Pettersson
Arne Berg
Jo Klaveness
Pal Rongved
Peter Leander
Ib Leunbach
Wolfgang Gunther
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare AS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9416767A external-priority patent/GB9416767D0/en
Priority claimed from GB9416768A external-priority patent/GB9416768D0/en
Application filed by Individual filed Critical Individual
Priority claimed from PCT/GB1995/001969 external-priority patent/WO1996005867A2/fr
Publication of CA2197466A1 publication Critical patent/CA2197466A1/fr
Abandoned legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

On décrit une composition de milieu de contraste qui contient un composé à base de manganèse tolérable du point de vue physiologique, un promoteur d'absorption et un vecteur ou excipient tolérable du point de vue physiologique. Sa concentration en manganèse est d'au moins 0,3 mM mais elle peut aussi se présenter sous une forme galénique contenant au moins 300 µmol de manganèse. Le promoteur d'absorption comprend un composé réducteur, tolérable du point de vue physiologique, qui contient un groupe .alpha.-hydroxy cétone, un acide tolérable du point de vue physiologique et contenant des groupes .alpha. et/ou .beta.-hydroxy ou amino ou un de leurs sels, et/ou de la vitamine D. Ces compositions conviennent particulièrement pour l'imagerie du foie.
CA002197466A 1994-08-18 1995-08-18 Compositions Abandoned CA2197466A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9416767A GB9416767D0 (en) 1994-08-18 1994-08-18 Compositions
GB9416767.3 1994-08-18
GB9416768A GB9416768D0 (en) 1994-08-18 1994-08-18 Compositions
GB9416768.1 1994-08-18
PCT/GB1995/001969 WO1996005867A2 (fr) 1994-08-18 1995-08-18 Compositions

Publications (1)

Publication Number Publication Date
CA2197466A1 true CA2197466A1 (fr) 1996-02-29

Family

ID=26305478

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002197466A Abandoned CA2197466A1 (fr) 1994-08-18 1995-08-18 Compositions

Country Status (6)

Country Link
EP (1) EP0776219A2 (fr)
JP (1) JPH10504559A (fr)
AU (1) AU688565B2 (fr)
CA (1) CA2197466A1 (fr)
FI (1) FI970667A (fr)
NZ (1) NZ291479A (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980863A (en) * 1998-11-02 1999-11-09 Eagle Vision Pharmaceutical Corporation Manganese compositions and methods for MRI

Also Published As

Publication number Publication date
EP0776219A2 (fr) 1997-06-04
AU3262095A (en) 1996-03-14
FI970667A0 (fi) 1997-02-17
AU688565B2 (en) 1998-03-12
FI970667A (fi) 1997-02-17
JPH10504559A (ja) 1998-05-06
NZ291479A (en) 1999-04-29

Similar Documents

Publication Publication Date Title
Zhang et al. Gadolinium meets medicinal chemistry: MRI contrast agent development
US5628983A (en) Squid magnetometry using paramagnetic metal chelates
CA2108362A1 (fr) Agents a base de melamine pour ameliorer la qualite des images
JPH0768193B2 (ja) 生理学的に認容性のｎｍｒ―造影剤用錯塩
US20090317327A1 (en) Aqueous Dispersion of Superparamagnetic Single-Domain Particles, Production and Use Thereof in Diagnosis and Therapy
JPH09502426A (ja) 像コントラスト増強のための方法および組成物
FI98986C (fi) Hiukkasten muodossa olevat varjoaineet
Richardson et al. Iron (III)-based contrast agents for magnetic resonance imaging
US6015545A (en) Manganese containing magnetic resonance contrast agent
ES2289099T3 (es) Compuestos a base de complejos de metal paramagnetico con ftalocianina y agente de contraste que los comprende.
WO1996005867A2 (fr) Compositions
US5560903A (en) Method of enhancing paramagnetism in chelates for MRI
JP2002528473A (ja) マンガン組成物及びｍｒｉのための方法
US6136292A (en) Determination of non-functioning areas of the g.i. tract using MRI of manganese composition
US5863519A (en) Composition and method of MRI using both a positive and a negative contrast agent
US5716598A (en) Contrast medium for magnetic resonance imaging using physiologically tolerable manganese compound
CA2197466A1 (fr) Compositions
US5985245A (en) Contrast agents for MRI using a manganese compound and kojic acid
WO1998011922A2 (fr) Procede
US5368839A (en) Insoluble salts of lanthanides for the visual display using nuclear magnetic resonance, of the gastro-intestinal tract
WO1998011921A2 (fr) Procede
Davis et al. Optimization of a negative oral contrast agent for magnetic resonance imaging
US20030064026A1 (en) Lipophilic metal complexes for necrosis and infarction imaging
WO2010099804A1 (fr) Imagerie par résonance magnétique du foie
JPH03284629A (ja) Ｍｒｉ用造影剤

Legal Events

Date Code Title Description
FZDE Discontinued